REG - Inspiration Health - Transfer of Non-Core Products to Focus on Neonatal

Inspiration HealthcareAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260602:nRSB5439Ga&default-theme=true

RNS Number : 5439G  Inspiration Healthcare Group PLC  02 June 2026

 

 

 

2 June 2026

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

Transfer of Non-Core Distributed Products to Focus on Neonatal

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology
company, announces that on 1 June 2026 it entered into a framework agreement
with Micrel Medical Devices SA ("Micrel") for the transfer of the distribution
of Micrel's infusion products to an entity controlled by Micrel effective from
31 January 2027.

 

The Group has been the exclusive distributor of Micrel's ambulatory infusion
pumps and related consumables in the United Kingdom since 2011. During this
time Inspiration Healthcare has built a market leading position in the
homecare market for parenteral nutrition and a growing presence in the NHS.
The infusion products generated revenue of £9.7million (unaudited) at a
contribution margin of approximately 25% for the Group in the year ended 31
January 2026.

 

Under the terms of the framework agreement, the existing distribution
agreement will expire on 31 January 2027 with Micrel taking full control for
the sale and distribution of the products in the UK.  The Inspiration
Healthcare employees responsible for the infusion products will transfer to
Micrel under TUPE from 1 July 2026. In addition, Micrel will buy back unsold
inventory on the final transfer date and make a compensation payment to
Inspiration Healthcare in exchange for the orderly transition of the business
and reflecting the goodwill generated during Inspiration's tenure as UK
distributor.

 

Inspiration Healthcare will continue to manage and sell the products during a
transition period until 31 January 2027 meaning there will be no impact on the
Group's revenue and gross profit estimates for the current financial year. The
transfer of employees to Micrel on 1 July will generate savings in operating
expenses in the second half. The Board expects these savings, combined with
the compensation payment, to contribute to reducing net debt by approximately
20% during FY27*.

 

Raffi Stepanian, CEO of Inspiration Healthcare commented: "This separation of
the infusion products allows the Group to focus on its core business of
neonatology and neonatal ventilation in particular. The Group has identified
opportunities to grow its product portfolio and footprint in this segment
through organic means as well as third party distribution opportunities and
continues to assess further opportunities."

 

*As at 31 January 2026, net debt (excluding IFRS16 lease liabilities) stood at
£5.1m

 

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No.
596/2014. Upon the publication of this announcement, this inside information
is now considered to be in the public domain.

 

For further information, please contact:

 

 Inspiration Healthcare Group plc                                                               Tel: +44 (0)330
                                                                175 0000
 Raffi Stepanian, Chief Executive Officer
 Alan Olby, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser & Broker)                                                                              Tel: +44 (0)20 3100 2000
 Alex Bond
 Jalini Kalaravy

 Cavendish Capital Markets (Joint Broker)                                             Tel: + 44 (0)20 7220 0500
 Giles Balleny / Joe Smith
 Nigel Birks
 Harriet Ward

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
                                   (mailto:inspirationhealthcare@walbrookpr.com)
 Anna Dunphy                                                    Mob: +44 (0) 7876 741 001
 Rachel Broad                                                   Mob: +44 (0) 7747 515 393

 

 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering
medical technology. Based in the UK, the Company specialises in neonatal
intensive care medical devices, which are addressing a critical need to help
to save the lives and improve the outcomes of patients, starting with the very
first breaths of life.

 

The Company has a broad portfolio of its own products and complementary
distributed products, for use in neonatal intensive care designed to support
even the most premature babies throughout their hospital stay. Its own branded
products range from highly sophisticated capital equipment such as ventilators
for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers
in the UK and Ireland, where it also distributes a range of advanced medical
technologies for infusion therapy. In the rest of the world the Company has an
established network of distribution partners around the world giving access to
more than 75 countries.

 

The Company operates in the UK from its world-class Manufacturing and
Technology Centre in Croydon, South London and in the USA from its facility in
Melbourne, Florida.

 

Further information on Inspiration Healthcare can be found at
www.inspirationhealthcaregroup.com (http://www.inspirationhealthcaregroup.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUPUCCQUPQGMG



            Copyright 2019 Regulatory News Service, all rights reserved